The drug company Perrigo agreed Monday to acquire the Irish biotechnology company Elan in a cash-and-stock deal worth $6.7 billion. Under the terms of the deal, Perrigo said it would offer $16.50 in cash and shares to Elan’s shareholders, 11 percent above Elan’s closing share price in New York on Friday.

— From wire reports